Elisabet de los Pinos, Aura Biosciences CEO

In­tra­cel­lu­lar tar­gets, eye can­cer ther­a­py and light-ac­ti­vat­ed skin­care: Here's the lat­est on biotech IPOs

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The busy IPO sea­son shows no sign of slow­ing, with three more biotechs trick-or-treat­ing for their own stock tick­ers and some sweet rais­es Thurs­day.

En­tra­da Ther­a­peu­tics, Biofron­tera Inc. and Au­ra Bio­sciences — all based in Mass­a­chu­setts — hit Nas­daq just be­fore the end of the week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.